Tema Etfs LLC Has $3.12 Million Holdings in Merus N.V. $MRUS

Tema Etfs LLC trimmed its position in shares of Merus N.V. (NASDAQ:MRUS) by 35.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,134 shares of the biotechnology company’s stock after selling 18,081 shares during the period. Tema Etfs LLC’s holdings in Merus were worth $3,120,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of MRUS. Farther Finance Advisors LLC lifted its holdings in shares of Merus by 10,400.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 520 shares during the period. CWM LLC raised its position in Merus by 299.0% during the second quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 601 shares in the last quarter. NTV Asset Management LLC bought a new stake in Merus during the third quarter worth $212,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Merus by 15.7% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 362 shares in the last quarter. Finally, Three Seasons Wealth LLC bought a new position in shares of Merus in the 3rd quarter valued at $284,000. 96.14% of the stock is owned by institutional investors.

Insider Activity at Merus

In other Merus news, VP Harry Shuman sold 8,300 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $95.92, for a total value of $796,136.00. Following the completion of the transaction, the vice president directly owned 11,002 shares in the company, valued at approximately $1,055,311.84. This represents a 43.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder A/S Genmab purchased 1,052,806 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were acquired at an average price of $97.00 per share, for a total transaction of $102,122,182.00. Following the acquisition, the insider owned 73,884,293 shares of the company’s stock, valued at $7,166,776,421. This trade represents a 1.45% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders acquired 2,421,216 shares of company stock valued at $234,857,952. Corporate insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on MRUS shares. Truist Financial lowered Merus from a “buy” rating to a “hold” rating and raised their price objective for the company from $88.00 to $97.00 in a research note on Monday, September 29th. BMO Capital Markets reissued a “market perform” rating and issued a $97.00 target price on shares of Merus in a report on Friday, October 31st. HC Wainwright lowered shares of Merus from a “buy” rating to a “neutral” rating and decreased their price target for the company from $135.00 to $97.00 in a report on Monday, September 29th. Leerink Partnrs cut shares of Merus from a “strong-buy” rating to a “hold” rating in a research report on Sunday, October 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Merus in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $93.56.

Merus Price Performance

Merus stock opened at $90.00 on Monday. The business has a 50 day moving average of $94.93 and a 200-day moving average of $80.07. The company has a market capitalization of $6.83 billion, a P/E ratio of -16.98 and a beta of 1.06. Merus N.V. has a 1 year low of $33.19 and a 1 year high of $97.14.

About Merus

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.